Akèy › Lukemi lenfositè kwonik › Florid › Jacksonville
Etid klinik pou Lukemi lenfositè kwonik nan Jacksonville, FL
11 etid pou Lukemi lenfositè kwonik ap chèche patisipan nan sit nan ak bò kote Jacksonville (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
Ap rekriteFaz 1/2
- Mayo Clinic Jacksonville, Jacksonville
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
Ap rekriteFaz 3
- Mayo Clinic Jacksonville, Jacksonville
A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
Ap rekriteFaz 3
- Baptist Md Anderson Cancer Center, Jacksonville
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Ap rekriteFaz 3
- Mayo Clinic Jacksonville, Jacksonville
- Cancer Specialists of North Florida, Jacksonville
A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Ap rekriteFaz 4
- Cancer Specialists, LLC, Jacksonville
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
Ap rekriteFaz 3
- Mayo Clinic - Jacksonville, Jacksonville
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
Ap rekriteFaz 1/2
- Mayo Clinic, Jacksonville
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
Ap rekriteFaz 1/2
- Mayo Clinic, Clinical Trials Referral Office, Jacksonville
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
Ap rekriteFaz 3
- Cancer Specialists of North Florida - Jacksonville - AC Skinner Parkway /ID# 266713, Jacksonville
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
Ap rekriteFaz 4
- Cancer Specialists, LLC, Jacksonville
B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies
Ap rekriteFaz 1
- Mayo Clinic in Florida, Jacksonville
Etid Lukemi lenfositè kwonik nan lòt vil
- Boston, MA31 etid
- Columbus, OH28 etid
- Durham, NC27 etid
- Washington, DC22 etid
- Seattle, WA20 etid
- Rochester, MN19 etid
- New York City, NY18 etid
- Houston, TX17 etid
- Baldwin Park, CA16 etid
- Milwaukee, WI15 etid
- Chicago, IL14 etid
- Cincinnati, OH14 etid
Lòt etid nan Jacksonville
- Kansè nan tete40 etid
- Kansè Poumon ki pa ti selil39 etid
- Kansè (tout kalite)29 etid
- Kansè Metastatik28 etid
- Kansè kolorektal27 etid
- Kansè pwostat26 etid
- Obèsite25 etid
- Ensifizyans kadyak21 etid
- Kansè pankreyas20 etid
- Sipwa19 etid
- Myelom Miltip18 etid
- Kansè poumon17 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.